La Jolla Pharmaceutical — Investor Presentation (April 2017)
36 slides from La Jolla Pharmaceutical's investor presentation, Apr 11, 2017
Slide 1: Corporate Presentation April 2017
April 2017 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases NASDAQ: LJPC Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the company’s future results of operations. These statements are only predictions or statements of c
Slide 3: Agenda
• Overview of LJPC • LJPC-501 (Synthetic Human Angiotensin II) for CRH • LJPC-401 (Synthetic Human Hepcidin) for Iron Overload • LJPC-30S Program (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 3
Slide 4: Mission Statement
Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life-threatening diseases by discovering and developing innovative therapies 4
Slide 5: LJPC Corporate Highlights
LJPC Corporate Highlights • Focused on de-risked product opportunities § Naturally occurring peptides with well-understood biological functions § Derivative components of FDA-approved products • LJPC-501 (synthetic human angiotensin II) for catecholamine-resistant hypotension (CRH) § Phase 3 registr
Slide 6: Product Pipeline
Product Pipeline UnderwayCompleted/milestone achieved Planned 6 LJPC-501 Synthetic Human Angiotensin II LJPC-401 Synthetic Human Hepcidin Other R&D Indication IND Phase 1 Phase 2 Phase 3 Catecholamine Resistant Hypotension Sept. 2016 Various Iron overload due to HH, Thalassemia, SCD and MDS Q4 2015
Slide 7: Agenda
• Overview of LJPC • LJPC-501 (Synthetic Human Angiotensin II) for CRH • LJPC-401 (Synthetic Human Hepcidin) for Iron Overload • LJPC-30S Program (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 7
Slide 8: LJPC-501: Overview
LJPC-501: Overview 8 • LJPC-501 is a proprietary formulation of synthetic human angiotensin II, a naturally occurring regulator of blood pressure being developed for catecholamine-resistant hypotension (CRH), dangerously low blood pressure • CRH is deadly, costly and prevalent • Phase 3 conducted un
Slide 9: Shock: Deadly, Costly and Prevalent
Shock MORTALITY RATES COMPARED Shock: Deadly, Costly and Prevalent 1. Vincent JL, De Backer D. N Engl J Med. 2013;369(18):1726-1734. 2. Sviri S, Hashoul J, Stav I, van Heerden PV. J Crit Care. 2014;29(1):157-160. 3. Readmissions and deaths-national. Data.Medicare.gov website. https://data.medicare.g
Slide 10: CMS Covered Charges for CRH Population
CMS Covered Charges for CRH Population Are Much Greater Than for Other Acute Hospital Conditions 10 Source: CMS FY14 Inpatient Public Use File (IPUF) $87,282 $42,243 $31,453 $30,702 CRH AMI CHF Pneumonia Weighted Average CMS Covered Charges Abbreviations: AMI=acute myocardial infarction; CHF=congest
Slide 11: U.S. Shock Patient Population and Treatment Paradigm
U.S. Shock Patient Population and Treatment Paradigm 11 1. 9.42MM annualized vials (785K vials sold in January 2017 X 12); Symphony Health Solutions, 2017. 97% of vials sold for hypotensive shock; estimate based on medical literature. 13 vials used per patient; estimate based on Russell et al, N Eng
Slide 12: Randomized Study of Vasopressin VASST Overall Survival
Randomized Study of Vasopressin 12 VASST Overall Survival1 VASST=Vasopressin and Septic Shock Trial 1. Russell JA, Walley KR, Singer J, et al. for VASST Investigators. N Engl J Med. 2008;358(9):877-887 Day 28 HR=0.90 (95%CI: 0.75-1.08) P=0.27 Day 90 HR=0.88 (95%CI: 0.76-1.03) P=0.10
Slide 13: LJPC-501: First Synthetic Human Angiotensin II Tested in Randomized Phase 3
LJPC-501: The First Synthetic Human Angiotensin II Tested in a Randomized Phase 3 Study 13 • LJPC-501 is a proprietary formulation of synthetic human angiotensin II, a naturally occurring regulator of blood pressure • Angiotensin II has been shown to raise blood pressure in a randomized, placebo-con
Slide 14: Three Systems Work in Harmony to Regulate Blood Pressure
Three Systems Work in Harmony to Regulate Blood Pressure Existing Treatments for Shock Only Utilize Two Systems THERAPIES AND ASSOCIATED ADVERSE EVENTS SYMPATHETIC NERVOUS ARGININE- VASOPRESSIN RENIN ANGIOTENSIN- ALDOSTERONE 14 CATECHOLAMINES1: SYMPATHETIC NERVOUS Prolonged elevated heart rate, tach
Slide 15: ATHOS-3 Study Design
Primary endpoint Percentage of patients achieving pre-specified target blood pressure response1 ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) Study Design 15 1. Specifically, percentage of patients achieving a Mean Arterial Pressure (MAP) ≥ 75 mmHg OR a 10 mmHg increase from baseli
Slide 16: ATHOS-3 Topline Results: Primary Endpoint
ATHOS-3 Topline Results: Primary Endpoint Primary Efficacy Endpoint Placebo LJPC-501 P-Value Percentage of patients achieving pre-specified target blood pressure response1 23% 70% <0.00001 16 • Analysis of primary efficacy endpoint was highly statistically significant 1. Specifically, percentage of
Slide 17: ATHOS-3 Topline Results: Mortality
ATHOS-3 Topline Results: Mortality Estimated Risk Reduction Hazard Ratio 1 95% Confidence Interval P-Value 22% 0.78 0.57-1.07 0.12 1. Proportional hazards estimate (unadjusted) of mortality to Day 28 comparing placebo-treated patients to LJPC-501-treated patients 17 • Trend toward longer survival ob
Slide 18: ATHOS-3 Topline Results: Safety
ATHOS-3 Topline Results: Safety Placebo LJPC-501 Percentage of patients experiencing at least one adverse event 92% 87% Percentage of patients discontinuing treatment due to an adverse event 22% 14% 18 • Throughout the study, safety outcomes were followed by an independent Data Safety Monitoring Boa
Slide 19: LJPC-501: Path Forward
LJPC-501: Path Forward 19 • Phase 3 conducted under Special Protocol Assessment (SPA) § Agreement reached that blood pressure can be the primary endpoint for approval • Phase 3 positive topline results: primary efficacy endpoint highly statistically significant, trend toward longer survival • ATHOS-
Slide 20: Agenda
• Overview of LJPC • LJPC-501 (Synthetic Human Angiotensin II) for CRH • LJPC-401 (Synthetic Human Hepcidin) for Iron Overload • LJPC-30S Program (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 20
Slide 21: LJPC-401: Overview
LJPC-401: Overview • LJPC-401 is a proprietary formulation of synthetic human hepcidin, a naturally occurring regulator of iron absorption and distribution • Primary iron overload § Hereditary hemochromatosis (HH) is characterized by a genetic deficiency of hepcidin resulting in excessive iron accum
Slide 22: Hepcidin: The Insulin of Iron Metabolism
Hepcidin: The Insulin of Iron Metabolism • Hepcidin: the insulin of iron metabolism § Regulates iron absorption and disposition in all organs § Rapid and sustained lowering of iron levels • Progress § SC formulation developed § Orphan Drug Designation granted (EU) § Positive Phase 1 study results §
Slide 23: LJPC-401: Phase 1 Study Design
PRIMARY ENDPOINT Safety and tolerability via review of: Treatment Emergent Adverse Events (TEAEs), changes in clinical lab values, ECGs, vital sign and physical exam data SECONDARY ENDPOINT Serum iron LJPC-401: Phase 1 Study Design • Population: Adult patients at risk of iron overload (e.g., HH, tha
Slide 24: LJPC-401: Phase 1 Results Overview
LJPC-401: Phase 1 Results Overview • Fifteen patients dosed at escalating dose levels from 1 mg to 20 mg § Patient subtypes treated: HH = 10; SCD = 3; and thalassemia = 2 • Safety observations § No dose-limiting toxicities at any dose level § 1 SAE at 1 mg dose level unrelated to study drug – Hospit
Slide 25: LJPC-401: Percent Change in Serum Iron, Baseline to Hour 8
Dose Response p=0.008 Individual dose p-values for change from baseline not adjusted for a potential regression to the mean effect. Dose response not adjusted for multiple comparisons. LJPC-401: Percent Change in Serum Iron Baseline to Hour 8 25
Slide 26: LJPC-401: Percent Change in Serum Iron Through Day 7
Nominal Time from Treatment (hours) Pe rc en t C ha ng e fro m B as el in e (% ) 0 8 24 48 168 -100 -75 -50 -25 0 25 Serum Iron: Percent Change from Baseline Change from baseline through day 7: -21% LJPC-401: Percent Change in Serum Iron Baseline through Day 7 for 20 mg Dose 26
Slide 27: LJPC-401: Update on Registration Plan
• Agreement reached with European Medicines Agency (EMA) on pivotal study design • Randomized, controlled, multi-center study in beta thalassemia patients suffering from iron overload § A major unmet medical need in an orphan patient population • Primary endpoint is a clinically relevant measurement
Slide 28: LJPC-401: Patient Need
LJPC-401: Patient Need • Hereditary Hemochromatosis (HH) § Most common genetic disease in Caucasians § Silent Killer - Iron accumulation can lead to liver cirrhosis, liver cancer, heart disease and/or failure, and diabetes § No FDA-approved treatment § Current treatments don’t address the underlying
Slide 29: Agenda
• Overview of LJPC • LJPC-501 (Synthetic Human Angiotensin II) for CRH • LJPC-401 (Synthetic Human Hepcidin) for Iron Overload • LJPC-30S Program (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 29
Slide 30: LJPC-30S: Overview
LJPC-30S: Overview • LJPC-30S is a purified derivative of gentamicin, which retains biologic activity but lacks traditional kidney toxicity • Gentamicin: FDA-approved, standard-of-care for serious Gram- negative bacterial infections § Mixture of several distinct but closely related chemical entities
Slide 31: LJPC-30S: Potential for Improved Clinical Profile
Next-generation improved gentamicin derivative 1. Retain activity LJPC-30S: Potential for Improved Clinical Profile 31 2. Improve safety 0.0 4.0 8.0 12.0 16.0 placebo next-generation gentamicin derivative gentamicinIn hi bi tio n/ ki ll zo ne (m m ) B.subtilus K.pneumonieae (kill) K.pneumonieae (inh
Slide 32: LJPC-30S: Current Antibiotic Usage
LJPC-30S: Current Antibiotic Usage • Antibiotic opportunity = $500+ million per year in U.S.1 § Market could expand with a safer alternative – Increased duration of therapy, increased penetration, and/or new indications • Other large potential market opportunity in rare genetic diseases, such as cys
Slide 33: Agenda
• Overview of LJPC • LJPC-501 (Synthetic Human Angiotensin II) for CRH • LJPC-401 (Synthetic Human Hepcidin) for Iron Overload • LJPC-30S Program (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Diseases • Financial Position Agenda 33
Slide 34: Financial Position
Financial Position 34 Condensed Balance Sheet Data As of December 31, 2016 (in millions) Cash1 $183.2 Total liabilities $9.8 Total shareholders’ equity1 $178.5 Fully Diluted, As-Converted Shares Outstanding2 32,205,772 1 Includes the effect of $117.5 million net proceeds received from the March 28,
Slide 35: LJPC Corporate Highlights
LJPC Corporate Highlights • Focused on de-risked product opportunities § Naturally occurring peptides with well-understood biological functions § Derivative components of FDA-approved products • LJPC-501 (synthetic human angiotensin II) for catecholamine-resistant hypotension (CRH) § Phase 3 study u
Slide 36: La Jolla Pharmaceutical social handle
a @Lavolla Pharmaceutical
LA Jolla Pharmaceutical — Investor Presentation (April 2017) on 6ix